List of articles with "Innovent"

First IL-23p19 Antibody

First IL-23p19 Antibody

China Suzhou Psoriasis Innovent PECONDLE
Mazdutide 9 mg Weight Loss

Mazdutide 9 mg Weight Loss

China Suzhou obesity Innovent Mazdutide
Innovent IBI3016 Data

Innovent IBI3016 Data

China Suzhou Innovent SanegeneBio IBI3016
Mazdutide vs. Semaglutide

Mazdutide vs. Semaglutide

China Suzhou Semaglutide Innovent Mazdutide
Innovent Cancer Innovations

Innovent Cancer Innovations

China Suzhou Cancer Treatment Innovent Oncology R&D
Hori's New Role

Hori's New Role

Japan Tokyo Innovent Japan Exhibition Association Masato Hori
Mazdutide at ADA 85

Mazdutide at ADA 85

China Suzhou Innovent Mazdutide ADA 85
Innovent's Research at ADA

Innovent's Research at ADA

China Suzhou Innovent Mazdutide IBI3030
Innovent's IBI354 Data Revealed

Innovent's IBI354 Data Revealed

China Suzhou Innovent IBI354 ASCO2025
Mazdutide Study in China

Mazdutide Study in China

China Suzhou Innovent NEJM Mazdutide
Innovent's New Antibody Developments

Innovent's New Antibody Developments

USA Chicago Innovent Bispecific Antibodies Tri-specific Antibodies
NMPA Approves Limertinib

NMPA Approves Limertinib

China Suzhou Lung Cancer Innovent Limertinib
Innovent at ASCO 2025

Innovent at ASCO 2025

USA Chicago IBI343 Innovent IBI363
Innovent Phase 3 Trials

Innovent Phase 3 Trials

China Suzhou Innovent IBI354 HER2 ADC
Breakthrough in RCC Treatment

Breakthrough in RCC Treatment

China Suzhou Innovent Sintilimab HUTCHMED
SYCUME® is Approved!

SYCUME® is Approved!

China Suzhou Innovent Thyroid Eye Disease SYCUME
DOVBLERON's Approval Boosts Lung Cancer Hope

DOVBLERON's Approval Boosts Lung Cancer Hope

China Suzhou Lung Cancer DOVBLERON Innovent
Innovent's DOVBLERON® Approval

Innovent's DOVBLERON® Approval

China Suzhou DOVBLERON Innovent ROS1 Inhibitor

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.